Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice

Brain Research
|February 3, 1987
PubMed

Insights

MPTP administration in mice depleted striatal dopamine levels and affected locomotion. Unlike other neurotoxins, MPTP did not cause nigral cell loss or axon swelling in this study.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Toxicology

Background:

  • MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin used to model Parkinson's disease.
  • Understanding MPTP's effects is crucial for Parkinson's disease research.

Purpose of the Study:

  • To investigate the histochemical, biochemical, and behavioral effects of MPTP in C-57 black mice.
  • To compare MPTP's neurotoxic profile with other agents like 6-hydroxydopamine.

Main Methods:

  • Daily MPTP administration (30 mg/kg) or vehicle for 10 days.
  • Behavioral assessment (open field test) at 0.5h, 24h, and 7 days post-injection.
  • Biochemical assays for striatal dopamine levels.
  • Histochemical analysis of brain tissue.

Main Results:

  • MPTP significantly reduced striatal dopamine levels (14-27% of control).
  • Behavioral changes included initial locomotion impairment and later facilitation.
  • Histochemistry confirmed severe depletion of striatal dopamine terminals without nigral cell body damage or axon swelling.

Conclusions:

  • MPTP induces striatal dopamine depletion and behavioral alterations in C-57 black mice.
  • MPTP's mechanism differs from 6-hydroxydopamine, as it spares nigral neurons and axons.
  • The observed effects suggest MPTP causes dopamine terminal damage without significant neuronal loss in this model.

Related Concept Videos